The determination of bromazepam in plasma by reversed-phase high-performance liquid chromatography.
A reversed-phase high-performance liquid chromatographic method has been developed for the determination of bromazepam, an anxiolytic benzodiazepine, in plasma. After a single-step extraction from alkalinized plasma with diethyl-ether in the presence of an internal standard (alpha-hydroxy-triazolam), the residues were chromatographed on a reversed-phase Nova Pak 5 microns C18 column, with a mobile phase of acetonitrile-water-triethylamine (700:300:4, v/v/v) adjusted to pH 7.4 with orthophosphoric acid. The limit of detection was 50 ng ml-1, using a 20 microliters injection with UV detection at 240 nm. Between-day and within-day relative standard deviations were lower than 6%. Studies of drug stability during sample storage at -20 degrees C and at +4 degrees C showed no degradation of bromazepam. However, bromazepam seemed to be degraded at ambient temperature, without any influence of light. This method is applied to the determination of bromazepam plasma levels in analytical toxicology.
Le Solleu
H
H
Department of Clinical Pharmacology and Toxicology, CHU, Bordeaux, France.
Demotes-Mainard
F
F
Vinçon
G
G
Bannwarth
B
B
D001569:Benzodiazepines / Q000097:blood*; D001960:Bromazepam / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D004986:Ether / Q000737:chemistry; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008027:Light; D012015:Reference Standards; D013696:Temperature
D004986:Ether; D001569:Benzodiazepines; D001960:Bromazepam